ICON PLC (ICLR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ICON PLC (ICLR) has a cash flow conversion efficiency ratio of 0.030x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($277.53 Million) by net assets ($9.38 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ICON PLC (ICLR) total market value for the company's overall valuation and market capitalisation.
ICON PLC - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how ICON PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ICON PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ICON PLC ranked by their cash flow conversion efficiency. Explore earnings quality score of ICON PLC to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taiwan Cooperative Financial Holding Co Ltd
TW:5880
|
-0.080x |
|
Assurant, Inc.
NYSE:AIZ
|
0.075x |
|
Lingyi iTech Guangdong Co
SHE:002600
|
0.086x |
|
LTIMindtree Limited
NSE:LTM
|
0.150x |
|
COSCO Shipping Energy Transportation Co Ltd
SHG:600026
|
0.062x |
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
0.119x |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
0.018x |
|
NESTE OYJ UNSP.ADR 1/2
F:NEFA
|
N/A |
Annual Cash Flow Conversion Efficiency for ICON PLC (1998–2025)
The table below shows the annual cash flow conversion efficiency of ICON PLC from 1998 to 2025. View ICLR live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.19 Billion | $1.04 Billion | 0.113x | -16.58% |
| 2024-12-31 | $9.52 Billion | $1.29 Billion | 0.135x | +7.54% |
| 2023-12-31 | $9.24 Billion | $1.16 Billion | 0.126x | +89.54% |
| 2022-12-31 | $8.50 Billion | $563.32 Million | 0.066x | -35.51% |
| 2021-12-31 | $8.07 Billion | $829.14 Million | 0.103x | -68.02% |
| 2020-12-31 | $1.85 Billion | $594.72 Million | 0.321x | +26.07% |
| 2019-12-31 | $1.62 Billion | $412.54 Million | 0.255x | +33.88% |
| 2018-12-31 | $1.39 Billion | $264.01 Million | 0.190x | -38.84% |
| 2017-12-31 | $1.23 Billion | $383.08 Million | 0.311x | +13.54% |
| 2016-12-31 | $945.17 Million | $259.20 Million | 0.274x | -25.03% |
| 2015-12-31 | $764.20 Million | $279.53 Million | 0.366x | +104.52% |
| 2014-12-31 | $950.21 Million | $169.95 Million | 0.179x | -26.38% |
| 2013-12-31 | $910.58 Million | $221.23 Million | 0.243x | +61.14% |
| 2012-12-31 | $754.58 Million | $113.77 Million | 0.151x | +408.94% |
| 2011-12-31 | $681.54 Million | $20.19 Million | 0.030x | -77.30% |
| 2010-12-31 | $670.00 Million | $87.43 Million | 0.130x | -70.72% |
| 2009-12-31 | $572.25 Million | $255.07 Million | 0.446x | +150.26% |
| 2008-12-31 | $456.37 Million | $81.28 Million | 0.178x | +61.55% |
| 2007-12-31 | $389.71 Million | $42.97 Million | 0.110x | -33.60% |
| 2006-12-31 | $303.86 Million | $50.45 Million | 0.166x | +192.11% |
| 2005-12-31 | $242.45 Million | $13.78 Million | 0.057x | -71.77% |
| 2004-12-31 | $216.76 Million | $43.64 Million | 0.201x | +11.01% |
| 2003-12-31 | $118.46 Million | $21.48 Million | 0.181x | +15.57% |
| 2002-12-31 | $136.91 Million | $21.48 Million | 0.157x | -12.45% |
| 2001-12-31 | $96.35 Million | $17.27 Million | 0.179x | +1011.45% |
| 2000-12-31 | $79.84 Million | $-1.57 Million | -0.020x | -118.03% |
| 1999-12-31 | $77.05 Million | $8.40 Million | 0.109x | +411.04% |
| 1998-12-31 | $70.30 Million | $1.50 Million | 0.021x | -- |
About ICON PLC
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It… Read more